Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this

Author: Keystone Heart

American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR

Data Supports Potential Need for TriGuard™ Cerebral Embolic Protection device being developed by Keystone Heart American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR CAESAREA, Israel & TAMPA, Fla.--September 30, 2016 — Keystone Heart Ltd., an emerging medical device company focused...

TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures

New data presented at PCR London Valves conference TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures CAESAREA, Israel & TAMPA, Fla.--September 19, 2016 — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for...

Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR

Supporting data to be presented at Transcatheter Valve Therapies (TVT) Conference Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR CAESAREA, Israel & TAMPA, Fla.--(BUSINESS WIRE)--Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients...

TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures

Benefits of Keystone Heart’s TriGuard neuroprotection during TAVR in reducing stroke, CNS infarction and infarction size are supported by results from pooled analysis presented at EuroPCR 2016 TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures Benefits of...

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9%...

Keystone Heart’s TriGuard™ Cerebral Protection Device Receives CE Marking

  CE Marking for the TriGuard™ device, devised to minimize the risk of brain damage during TAVR, enables commencement of commercial use Recent data demonstrates considerable reduction of new brain lesion volume during protected TAVR procedures performed with the TriGuard medical device Keystone Heart’s TriGuard™ Cerebral Protection Device...